Gallbladder Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The gallbladder treatment market size was valued at USD 9.92 billion in 2025 and is estimated to grow from USD 10.81 billion in 2026 to reach USD 16.61 billion by 2031, at a CAGR of 8.97% during the forecast period (2026-2031). This report is segmented by Disease Indication (Gallstones, Cholecystitis, and Biliary Colic, Gallbladder Polyps, and More), Diagnosis and Treatment (Diagnosis and Treatment), End Users (Hospitals, Ambulatory Surgical Centers, Gastroenterology and Specialty Clinics, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Gallbladder Treatment Market Trends and Insights

Rising Gallstone and Biliary Disease Burden

Gallbladder and biliary disease caused 73.2 million new cases globally in 2021, compared with 45.7 million cases in 1990, with population growth and aging accounting for much of the increase. Global prevalence is projected to rise 27.3% by 2035, while deaths are projected to increase from 136,221 to 186,486, extending demand beyond high-income care systems. South America had a gallstone prevalence of 11.2%, compared with the 6.1% global average, and Chile and Bolivia had among the highest gallbladder cancer mortality rates. Western Sub-Saharan Africa was the only region where DALY rates and mortality rates both increased between 1990 and 2021, pointing to substantial unmet access to laparoscopic treatment. Patients in lower-income settings may reach care later, and the mortality concentration index increased from 0.24 in 1990 to 0.31 in 2021. The gallbladder treatment market needs practical laparoscopic capacity, timely imaging, and providers that can combine emergency surgery with biliary endoscopy, because disease growth does not guarantee treatment access.

Preference for Minimally Invasive Cholecystectomy

Laparoscopic cholecystectomy remains the central surgical approach for most gallstone cases, while robotic surgery is being adopted at tertiary centers with sufficient capital and training. A study of 23,513 patients found a 0.65% bile duct injury rate with robotic cholecystectomy, compared with 1.02% with laparoscopic procedures, with fewer conversions to open surgery, shorter stays, and lower 30-day readmission and mortality. In December 2025, the U.S. Food and Drug Administration cleared Intuitive Surgical’s da Vinci SP system for cholecystectomy, extending single-incision robotic access to abdominal procedures. The gallbladder treatment market is developing along 2 paths, with tertiary centers using robotic platforms and other hospitals relying on laparoscopic instruments. Standard multiport instruments face pricing pressure where robotic systems are established, while single-use laparoscopic disposables remain relevant where robots are not financially feasible. This split makes clinical outcomes, operating time, case volume, devices, training, and service contracts important in hospital purchasing decisions.

High Procedure, Equipment, and Skilled-Workforce Costs

Robotic cholecystectomy costs USD 5,000 to USD 6,000 per procedure in Western centers, while laparoscopic surgery costs USD 2,000 to USD 3,000. Disposable costs averaged USD 1,309 for a robotic case and USD 534 for a laparoscopic case in a multicenter analysis. The difference limits access where public reimbursement sets procedure prices, including Brazil’s SUS and India’s PMJAY. Workforce shortages also limit same-day care because anesthesiology capacity and robotic training are required. Device companies use consumable agreements and training subsidies, but these measures do not remove the basic cost gap. Secondary hospitals may be unable to justify robotic certification or the procedure volume it requires, so equipment makers need choices suited to tertiary and lower-cost settings. The gallbladder treatment market can expand access only when diagnostic capacity is matched by trained staff and operating capacity across APAC, South America, the Middle East, and Africa.

Other drivers and restraints analyzed in the detailed report include:

• Aging, Obesity, Diabetes, and Metabolic Risk Clustering
• Fluorescence and Decision-Support Tools Improving Bile-Duct Visualization
• Bile-Duct Injury, Infection, Leakage, and Postcholecystectomy Risks

Segment Analysis

Gallstones held 63.47% of the gallbladder treatment market share within disease-indication revenue in 2025. The position reflects their prevalence and their role as the main clinical reason for cholecystectomy. Gallstones affect an estimated 10% to 20% of adults in Western populations. Germany performed 175,000 cholecystectomies annually, with 90% conducted laparoscopically. France performed 57,568 reimbursed cholecystectomies in 2025, and more than 90% used laparoscopy. Acute cholecystitis and biliary colic add a significant emergency-care workload to the high volume of elective gallstone treatment.

Biliary dyskinesia and postcholecystectomy syndrome are receiving more clinical attention as non-stone motility conditions. They are particularly relevant for female patients and people who have undergone metabolic surgery. Gallbladder cancer is the fastest-growing indication, at a 9.23% CAGR from 2026 to 2031. The FDA granted accelerated approval to zanidatamab-hrii in November 2024 for previously treated HER2-positive biliary tract cancer. The approval was supported by a 52% objective response rate and a 14.9-month median duration of response. In May 2026, the FDA approved zenocutuzumab-zbco for NRG1 fusion-positive cholangiocarcinoma, adding a targeted option for this molecular subtype.

Complete Report Scope:

• By Disease Indication
  • Gallstones
  • Cholecystitis and Biliary Colic
  • Cholelithiasis and Choledocholithiasis
  • Gallbladder Polyps
  • Gallbladder Cancer
  • Biliary Dyskinesia
  • Postcholecystectomy Syndrome
• By Diagnosis and Treatment
  • Diagnosis
    • Ultrasound
    • Liver Function Blood Tests
    • Computerized Tomography
    • Magnetic Resonance Cholangiopancreatography
    • Endoscopic Retrograde Cholangiopancreatography
    • Other Diagnosis Methods
  • Treatment
    • Surgical Treatment
      • Laparoscopic Cholecystectomy
      • Open Cholecystectomy
      • Robotic-Assisted Cholecystectomy
      • Percutaneous Cholecystostomy
    • Pharmacological Treatment
      • Ursodeoxycholic Acid
      • Chenodeoxycholic Acid and Chenodiol
      • Antibiotics and Supportive Medicines
    • Endoscopic & Minimally Invasive Treatment
      • Extracorporeal Shock-Wave Lithotripsy
      • ERCP-Based Bile-Duct Clearance
      • Endoscopic Stone Extraction
      • Other Minimally Invasive Interventions
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Gastroenterology and Specialty Clinics
  • Gynecology Clinics
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.62% of the gallbladder treatment market share in 2025. The gallbladder treatment market in the region benefits from a dense ambulatory surgery center network and an advanced base of minimally invasive surgical capability. Changes to the ambulatory surgery center covered procedure list support a wider range of biliary and gastrointestinal care settings. Canada is expanding day-case laparoscopic pathways through provincial health systems. Mexico’s private hospital network is increasing diagnostic and laparoscopic capacity in major urban centers. These conditions support procedure throughput, but hospital and payer requirements continue to determine which patients can safely use ambulatory care.

Asia-Pacific is the fastest-growing region, with a projected 12.49% CAGR from 2026 to 2031. The gallbladder treatment market in the region contains large untapped treatment volumes and uneven access to minimally invasive procedures. Guangdong Province General Hospital is using 3D and 4K fluorescence laparoscopy, 1.9 mm laparoscopic instruments, and 2.8 mm choledochoscopes for combined single-port cholecystectomy and bile duct stone extraction. The hospital reports that this pathway can support same-day discharge for procedures that earlier required 1-week inpatient stays. India represents a large volume opportunity because gallstone prevalence is estimated at 4% across a population of 1.4 billion. Japan, Australia, South Korea, and India are at different stages of adoption, so product design and pricing must vary across the region.

Europe has a significant gallbladder treatment market size because Germany, France, the United Kingdom, Italy, and Spain have established surgical systems. Germany’s annual 175,000 cholecystectomies and 90% laparoscopic rate demonstrate the scale of mature procedural care. Western Europe had the highest global prevalence rate of gallbladder and biliary disease, at 4,009.85 per 100,000 people. Brazil recorded more than 1.5 million hospitalizations for cholelithiasis and cholecystitis from 2020 to 2024. In the Middle East and Africa, Saudi Arabia and the UAE are adding tertiary capacity, while Western Sub-Saharan Africa has rising disease burden and limited treatment access.

List of Companies Covered in this Report:

• Pharmaceutical Companies
• Service Providers

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support